Poly (ADP-Ribose) Polymerase-1
"Poly (ADP-Ribose) Polymerase-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A poly(ADP-ribose) polymerase that contains two ZINC FINGERS in its N-terminal DNA-binding region. It modifies NUCLEAR PROTEINS involved in chromatin architecture and BASE EXCISION REPAIR with POLY ADENOSINE DIPHOSPHATE RIBOSE.
|Poly (ADP-Ribose) Polymerase-1
- Poly (ADP-Ribose) Polymerase-1
- Poly (ADP-Ribose) Synthase-1
- PARP1 Protein
- PARP-1 Protein
- PARP 1 Protein
- NAD+ ADP-ribosyltransferase-1
- NAD+ ADP ribosyltransferase 1
Below are MeSH descriptors whose meaning is more general than "Poly (ADP-Ribose) Polymerase-1".
Below are MeSH descriptors whose meaning is more specific than "Poly (ADP-Ribose) Polymerase-1".
This graph shows the total number of publications written about "Poly (ADP-Ribose) Polymerase-1" by people in this website by year, and whether "Poly (ADP-Ribose) Polymerase-1" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Poly (ADP-Ribose) Polymerase-1" by people in Profiles.
The three-dimensional structure of Epstein-Barr virus genome varies by latency type and is regulated by PARP1 enzymatic activity. Nat Commun. 2022 01 17; 13(1):187.
Up-Regulation of PARP1 Expression Significantly Correlated with Poor Survival in Mucosal Melanomas. Cells. 2020 05 05; 9(5).
Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer. Cancer Res. 2020 02 01; 80(3):394-405.
DNA damage-induced PARP1 activation confers cardiomyocyte dysfunction through NAD+ depletion in experimental atrial fibrillation. Nat Commun. 2019 03 21; 10(1):1307.
Poly(ADP-ribose) polymerase 1 is necessary for coactivating hypoxia-inducible factor-1-dependent gene expression by Epstein-Barr virus latent membrane protein 1. PLoS Pathog. 2018 11; 14(11):e1007394.
PARP1 Stabilizes CTCF Binding and Chromatin Structure To Maintain Epstein-Barr Virus Latency Type. J Virol. 2018 09 15; 92(18).
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res. 2017 Aug 01; 23(15):4066-4076.
Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression. J Natl Cancer Inst. 2016 10; 108(10).
Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression. Mol Cancer Ther. 2015 Nov; 14(11):2452-62.
The histone methyltransferase SMYD2 methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in cancer cells. Neoplasia. 2014 Mar; 16(3):257-64, 264.e2.